Study S000311

A Phase 1, Open-label, Single-Dose Study to Evaluate the Pharmacokinetics of AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07428525
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 36
Start: 2025-03-14
Primary completion: 2026-02-26
Lead sponsor: Amgen
Conditions: Hepatic Impairment
Interventions: DRUG:AMG 133
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120]
Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to Time of Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120]
AUC from Time Zero to Infinity (AUCinf) of AMG 133 [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.